Bioequivalence Study of Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg Under Fasting Conditions

• Status: Completed
• Trial end date: 2015-01-01

Summary

This is an open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, oral bioequivalence study in healthy, adult, human subjects under fasting conditions.

• Phase: Phase 1

Details

• Lead Sponsor: Dr. Reddy's Laboratories Limited
• Treatments: Chlorpheniramine, phenylpropanolamine drug combination; Ephedrine; Guaifenesin; Phenylpropanolamine; Pseudoephedrine